Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | IDE | P14735 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9346567 | 0.90 | TRPV1 (0.82) | TRPV1HSD17B10MAPTMEN1KMT2A | |
| SCHEMBL179009 | 0.88 | TRPV1 (0.79) | TRPV1MAPTMEN1KMT2ALMNA | |
| SCHEMBL9444656 | 0.88 | TRPV1 (0.78) | TRPV1MEN1KMT2APOLBHPGD | |
| SCHEMBL29548277 | 0.88 | TRPV1 (0.78) | TRPV1MAPTMEN1KMT2ATP53 | |
| SCHEMBL179093 | 0.87 | TRPV1 (0.77) | TRPV1MAPTMEN1KMT2APOLB | |
| SCHEMBL27407288 | 0.84 | EPHX2 (0.74) | TRPV1HSD17B10MAPTMEN1KMT2A | |
| SCHEMBL10946174 | 0.82 | TRPV1 (0.70) | TRPV1HPGDEPHX2 | |
| SCHEMBL29548418 | 0.82 | TRPV1 (0.70) | TRPV1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL10503254 | 0.82 | EPHX2 (0.84) | TRPV1MAPTMEN1KMT2ATP53 | |
| SCHEMBL178999 | 0.82 | TRPV1 (0.69) | TRPV1MEN1KMT2AUSP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753324-B1 | LIPOPHILIC DOPAMINE DERIVATIVES AND THEIR USE | NOVALIQ GMBH (DE) | 2017-12-20 | — | — | EP | disclosed |
| EP-2753324-B1 | LIPOPHILIC DOPAMINE DERIVATIVES AND THEIR USE | NOVALIQ GMBH (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-20140221485-A1 | LIPOPHILIC DOPAMINE DERIVATIVES AND THEIR USE | NOVALIQ GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20140221485-A1 | LIPOPHILIC DOPAMINE DERIVATIVES AND THEIR USE | NOVALIQ GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20140221485-A1 | LIPOPHILIC DOPAMINE DERIVATIVES AND THEIR USE | NOVALIQ GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
| WO-2013034457-A1 | LIPOPHILIC DOPAMINE DERIVATIVES AND THEIR USE | NOVALIQ GMBH (DE) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013034457-A1 | LIPOPHILIC DOPAMINE DERIVATIVES AND THEIR USE | NOVALIQ GMBH (DE) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221485-A1 | LIPOPHILIC DOPAMINE DERIVATIVES AND THEIR USE | SLC6A3, SLC6A2, DRD2 | TRPV1 431/4885HSD17B10 1127/4885MAPT 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.